制藥網(wǎng)>產(chǎn)品庫>原料藥中間體、制劑>生物試劑>其它試劑>>Deferoxamine mesylate試劑

Deferoxamine mesylate試劑

參考價	￥500.00-￥950.00

具體成交價以合同協(xié)議為準(zhǔn)

公司名稱杭州昊鑫生物科技股份有限公司
品牌MCE
型號HY-B0988
所在地杭州市
廠商性質(zhì)代理商
更新時間2023/5/29 15:12:20
訪問次數(shù)382

產(chǎn)品標(biāo)簽:

DFOM 甲磺酸去鐵胺

規(guī)格

10 mM * 1 mL in Water	550.00元	10000 可售
100 mg	500.00元	10000 可售
500 mg	950.00元	10000 可售

在線詢價收藏產(chǎn)品查看電話同類產(chǎn)品

聯(lián)系我們時請說明是制藥網(wǎng) 上看到的信息，謝謝!

索取相關(guān)資料

公司介紹主營產(chǎn)品

杭州昊鑫生物科技股份有限公司成立于2009年初，是一家面向生命科學(xué)領(lǐng)域，從事科研機構(gòu)、高校、院所及生產(chǎn)企業(yè)所需科研試劑、耗材，儀器銷售和服務(wù)面向全國。

產(chǎn)品和服務(wù)涵蓋生命科學(xué)研究技術(shù)的諸多方面，提供覆蓋分子生物學(xué)、細(xì)胞生物學(xué)、植物學(xué)、生物化學(xué)、蛋白組學(xué)、免疫學(xué)等領(lǐng)域的實驗產(chǎn)品以及生物技術(shù)服務(wù)等。目前一級代理品牌有：MCE（Medchemexpress）、Biochannel、AATbio、invivogen、Abnova、Atlas、Origene、Biovision、云克隆（Cloud-clone）、艾德萊(Aidlab)、Cayman、Jackson、Epigentek、Prospec、Sciencell、icellbioscience（賽百慷）、hkABCbio、chondrex、Mybiosource、Abbexa、Innovrsrch、HPI、Hitobiotec、Greerlabs，Ostex，4ADI，LDN等。

經(jīng)營理念：以誠信為本，保證產(chǎn)品質(zhì)量求生存，創(chuàng)造企業(yè)核心競爭力求發(fā)展 , 堅持用戶至上、服務(wù)至上的原則。

展開顯示更多內(nèi)容

胎牛血清、MCE抑制劑激動劑、RNA提取試劑盒、ELISA試劑盒、重組蛋白

產(chǎn)品簡介在線詢價

CAS號	138-14-7	產(chǎn)地	進口
級別	其他

Deferoxamine mesylate試劑
Deferoxamine mesylate (Deferoxamine B mesylate) 是一種鐵螯合劑 (結(jié)合 Fe(III) 和許多其他金屬陽離子)，被廣泛用于減少鐵在組織中的積累和沉積。Deferoxamine mesylate 可上調(diào) HIF-1α 水平，具有較好的抗氧化活性，還能抗增殖和誘導(dǎo)癌細(xì)胞凋亡。

Deferoxamine mesylate試劑產(chǎn)品信息

注：本產(chǎn)品僅用于科研，不可用于臨床

Deferoxamine mesylate試劑簡介

Deferoxamine mesylate (Deferoxamine B mesylate) 是一種鐵螯合劑 (結(jié)合 Fe(III) 和許多其他金屬陽離子)，被廣泛用于減少鐵在組織中的積累和沉積。Deferoxamine mesylate 可上調(diào) HIF-1α 水平，具有較好的抗氧化活性，還能抗增殖和誘導(dǎo)癌細(xì)胞凋亡。Deferoxamine mesylate 可用于糖尿病、神經(jīng)退行性疾病以及抗癌和抗疫情病毒的研究。

Deferoxamine mesylate試劑生物活性

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-疫情病毒

體外研究
(In Vitro)

Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells^[1].
Deferoxamine mesylate (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels^[2].
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs^[3].
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs^[3].
Deferoxamine mesylate (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs^[3].
Deferoxamine mesylate (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MEFs cells
Concentration:	1 mM
Incubation Time:	16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
Result:	Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

體內(nèi)研究
(In Vivo)

Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice^[1].
Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model)^[1].
Dosage:	560.68 mg/per (10 uL of 1 mM)
Administration:	Drip-on; once daily for 21 days.
Result:	Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.

分子量

656.79

性狀

Solid

Formula

C₂₆H₅₂N₆O₁₁S

CAS 號

138-14-7

中文名稱

甲磺酸去鐵胺；去鐵胺甲磺酸酯；甲磺酸去鐵敏；甲磺酸除鐵靈

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性數(shù)據(jù)

In Vitro:

H₂O : 250 mg/mL (380.64 mM; Need ultrasonic)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	1.5226 mL	7.6128 mL	15.2256 mL
5 mM	0.3045 mL	1.5226 mL	3.0451 mL
10 mM	0.1523 mL	0.7613 mL	1.5226 mL

請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 儲存時，請在 6 個月內(nèi)使用，-20°C 儲存時，請在 1 個月內(nèi)使用。

In Vivo:

請根據(jù)您的實驗動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨?。以下溶解方案都請先按?nbsp;In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：

——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶